.

Chemocentryx reported $43.34M in Operating Expenses for its second fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Operating Expenses Change
Abbvie ABBV:US $ 11288M 2467M
Alnylam Pharmaceuticals ALNY:US $ 416.5M 56.51M
Amgen AMGN:US $ 4.42B 680M
AstraZeneca AZN:LN 840.42B 39.99B
Bayer BAYN:GR 12.65B 2.22B
Biogen BIIB:US $ 2648.2M 727.1M
Biomarin Pharmaceutical BMRN:US $ 494.65M 112.61M
Bristol Myers Squibb BMY:US $ 9.3B 202M
Chemocentryx CCXI:US $ 43.34M 355K
GlaxoSmithKline GSK:LN 584.8B 95.1B
Glaxosmithkline GSK:US 5.85B 1.13B
Johnson & Johnson JNJ:US $ 18.18B 616M
Macrogenics MGNX:US $ 67.82M 9.92M
Merk MRK:US $ 9666M 666M
Mirati Therapeutics MRTX:US $ 182.57M 2.36M
Novartis NOVN:VX 10.86B 895M
Omeros OMER:US $ 37.44M 2.39M
Pfizer PFE:US $ 15640M 148M
Sarepta Therapeutics SRPT:US $ 444.62M 146.91M
Takeda 4502:JP 821.95B 52.96B
Teva Pharmaceutical TEVA:IT 4.74B 361M
YTE INCY:US $ 656.97M 40.27M